Immutep (ASX: IMM, NASDAQ: IMMP) continues to advance its immuno-oncology and autoimmune pipeline, with its lead candidate eftilagimod alpha (efti) showing encouraging results in clinical trials for non-small cell lung cancer (NSCLC) and head and neck cancer. Data from the TACTI-003 and TACTI-002 trials suggest efti’s potential as a combination therapy, with strong immune activation and response rates.
Beyond oncology, Immutep is progressing its autoimmune program with IMP761, a LAG-3-targeting therapy aimed at T-cell regulation. With ongoing collaborations, a solid cash position, and regulatory discussions on the horizon, the company is positioning efti for late-stage development while expanding its pipeline into new treatment areas.
